<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>CMC Seoul OBY &amp; Breast Pathology</title>
    <link>https://extraordinary-tulumba-269604.netlify.app/docs/</link>
    <description>Recent content on CMC Seoul OBY &amp; Breast Pathology</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Wed, 28 Nov 2018 15:14:39 +1000</lastBuildDate><atom:link href="https://extraordinary-tulumba-269604.netlify.app/docs/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Ki-67</title>
      <link>https://extraordinary-tulumba-269604.netlify.app/docs/breast/2022-10-18-ki-67/</link>
      <pubDate>Tue, 18 Oct 2022 00:00:00 +0000</pubDate>
      
      <guid>https://extraordinary-tulumba-269604.netlify.app/docs/breast/2022-10-18-ki-67/</guid>
      <description>Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
https://doi.org/10.1093/jnci/djaa201</description>
    </item>
    
    <item>
      <title>L1 cell adhesion molecule Immunohistochemistry</title>
      <link>https://extraordinary-tulumba-269604.netlify.app/docs/oby/2022-07-18-l1-cell-adhesion-molecule-immunohistochemistry/</link>
      <pubDate>Mon, 18 Jul 2022 00:00:00 +0000</pubDate>
      
      <guid>https://extraordinary-tulumba-269604.netlify.app/docs/oby/2022-07-18-l1-cell-adhesion-molecule-immunohistochemistry/</guid>
      <description>L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results
https://doi.org/10.1016/j.ejca.2014.07.014
L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile
https://doi.org/10.1038/s41416-018-0187-6</description>
    </item>
    
    <item>
      <title>Bethesda interobserver reproducibility data</title>
      <link>https://extraordinary-tulumba-269604.netlify.app/docs/2022-06-15-bethesda-interobserver-reproducibility-data/</link>
      <pubDate>Wed, 15 Jun 2022 00:00:00 +0000</pubDate>
      
      <guid>https://extraordinary-tulumba-269604.netlify.app/docs/2022-06-15-bethesda-interobserver-reproducibility-data/</guid>
      <description>Cytology reporting systemhttps://cytopathology.org/page/ReportingSystems
Bethesda interobserver reproducibility datahttps://bethesda.soc.wisc.edu/index.htm</description>
    </item>
    
    <item>
      <title>NCCN Guidelines</title>
      <link>https://extraordinary-tulumba-269604.netlify.app/docs/2022-06-13-nccn-guidelines/</link>
      <pubDate>Mon, 13 Jun 2022 00:00:00 +0000</pubDate>
      
      <guid>https://extraordinary-tulumba-269604.netlify.app/docs/2022-06-13-nccn-guidelines/</guid>
      <description>NCCN Guidelines category 1https://www.nccn.org/guidelines/category_1</description>
    </item>
    
    <item>
      <title>HER2 Testing in Breast Cancer - 2018 Focused Update</title>
      <link>https://extraordinary-tulumba-269604.netlify.app/docs/breast/2022-06-11-her2-testing-in-breast-cancer-2018-focused-update/</link>
      <pubDate>Sat, 11 Jun 2022 00:00:00 +0000</pubDate>
      
      <guid>https://extraordinary-tulumba-269604.netlify.app/docs/breast/2022-06-11-her2-testing-in-breast-cancer-2018-focused-update/</guid>
      <description>HER2 Testing in Breast Cancer - 2018 Focused Updatehttps://www.cap.org/protocols-and-guidelines/cap-guidelines/current-cap-guidelines/recommendations-for-human-epidermal-growth-factor-2-testing-in-breast-cancer</description>
    </item>
    
    <item>
      <title>International Immuno-Oncology Biomarker Working Group on Breast Cancer</title>
      <link>https://extraordinary-tulumba-269604.netlify.app/docs/breast/2022-06-11-international-immuno-oncology-biomarker-working-group-on-breast-cancer/</link>
      <pubDate>Sat, 11 Jun 2022 00:00:00 +0000</pubDate>
      
      <guid>https://extraordinary-tulumba-269604.netlify.app/docs/breast/2022-06-11-international-immuno-oncology-biomarker-working-group-on-breast-cancer/</guid>
      <description>International Immuno-Oncology Biomarker Working Group on Breast Cancerhttps://www.tilsinbreastcancer.org</description>
    </item>
    
    <item>
      <title>Lower Anogenital Squamous Terminology (LAST) for HPV-Associated Lesions</title>
      <link>https://extraordinary-tulumba-269604.netlify.app/docs/oby/2022-06-11-lower-anogenital-squamous-terminology-last-for-hpv-associated-lesions/</link>
      <pubDate>Sat, 11 Jun 2022 00:00:00 +0000</pubDate>
      
      <guid>https://extraordinary-tulumba-269604.netlify.app/docs/oby/2022-06-11-lower-anogenital-squamous-terminology-last-for-hpv-associated-lesions/</guid>
      <description>CAP guideline Lower Anogenital Squamous Terminology (LAST) for HPV-Associated Lesionshttps://www.cap.org/protocols-and-guidelines/cap-guidelines/current-cap-guidelines/cap-asccp-lower-anogenital-squamous-terminology-for-hpv-associated-lesions</description>
    </item>
    
    <item>
      <title>PD-L1 Interpretation Manual</title>
      <link>https://extraordinary-tulumba-269604.netlify.app/docs/breast/2022-06-11-pd-l1-ihc-22c3-pharmdx-interpretation-manual-triple-negative-breast-cancer-tnbc/</link>
      <pubDate>Sat, 11 Jun 2022 00:00:00 +0000</pubDate>
      
      <guid>https://extraordinary-tulumba-269604.netlify.app/docs/breast/2022-06-11-pd-l1-ihc-22c3-pharmdx-interpretation-manual-triple-negative-breast-cancer-tnbc/</guid>
      <description>VENTANA PD-L1 (SP142) Assay IC staininghttps://diagnostics.roche.com/content/dam/diagnostics/us/en/products/v/ventana-pd-l1-sp142-assay/VENTANA-PD-L1-SP142-Assay-TNBC-IG.pdf
PD-L1 IHC 22C3 pharmDx Interpretation Manual – Triple-Negative Breast Cancerhttps://www.agilent.com/cs/library/usermanuals/public/29389_22c3_pharmdx_tnbc_interpretation_manual_kn355.pdf
PD-L1 IHC 22C3 pharmDx Interpretation Manual – Cervical Cancerhttps://www.agilent.com/cs/library/usermanuals/public/29257_22c3_pharmDx_cervical_interpretation_manual_us.pdf</description>
    </item>
    
    <item>
      <title>FIGO</title>
      <link>https://extraordinary-tulumba-269604.netlify.app/docs/oby/2022-06-10-figo-cancer-report-2021/</link>
      <pubDate>Fri, 10 Jun 2022 00:00:00 +0000</pubDate>
      
      <guid>https://extraordinary-tulumba-269604.netlify.app/docs/oby/2022-06-10-figo-cancer-report-2021/</guid>
      <description>FIGO Cancer Report 2021FIGO staging and reporthttps://www.figo.org/news/figo-cancer-report-2021
</description>
    </item>
    
    <item>
      <title>Cancer Reporting and Biomarker Reporting Protocols</title>
      <link>https://extraordinary-tulumba-269604.netlify.app/docs/breast/2022-06-11-cancer-reporting-and-biomarker-reporting-protocols/</link>
      <pubDate>Sat, 11 Jun 2022 00:00:00 +0000</pubDate>
      
      <guid>https://extraordinary-tulumba-269604.netlify.app/docs/breast/2022-06-11-cancer-reporting-and-biomarker-reporting-protocols/</guid>
      <description>CAP Cancer Reporting and Biomarker Reporting Protocolshttps://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates#protocols</description>
    </item>
    
  </channel>
</rss>
